PledPharma AB Company Announcement PledPharma receives 500,000 SEK in VINNOVA financing Vinnova has decided to give PledPharma AB 500,000 SEK in financing from the “Forska & Väx” (Research & Grow) program. Stockholm, 2012-04-03 15:30 CEST (GLOBE NEWSWIRE) -- The financing will be used for preclinical studies to widen the PledOx project to also encompass side-effects during other cancer treatment than colorectal cancer treatment. For further information please contact: Jacques Näsström, CEO, cell: +46 73 713 0979 About PledPharma PledPharma is a Swedish specialty pharma company, which develops new treatments of life threatening diseases. PledPharma currently runs two projects in clinical development phase II with the patented drug substance class, PLED-derivatives. The preventive effect of PLED-derivatives on adverse effects of chemotherapy in colon cancer is examined in one trial. Another trial investigates the ability of PLED-derivatives to reduce reperfusion injuries in myocardial infarction patients undergoing percutaneous coronary intervention (PCI). PLED-derivatives protect the body’s normal cells against oxidative stress, which is a condition due to overproduction of free oxygen radicals. PLED-derivatives have in previous pre-clinical trials been shown to protect against oxidative stress. Moreover, the PLED-derivative mangafodipir protected against the side effects of chemotherapy in colorectal cancer. PledPharma (STO:PLED) is listed on NASDAQ OMX First North. Erik Penser Bankaktiebolag is the Certified Adviser. For more information, please visit www.pledpharma.se
